The company raised guidance for the end of the year and said Ranbaxy's being bounced from the Nexium competition probably means it has esomeprazole market to itself through 2014.
Cymbalta and Evista patent losses drove down sales, but Lilly said it does not plan to replenish the sales force it thinned in anticipation of the decline.
GlaxoSmithKline's third-quarter sales fell 10% for the quarter, compared to last year, and new Ellipta products failed to cushion the 24% drop in US Advair sales.
Hepatitis C medication Olysio contributed to the the 18% bump in Johnson & Johnson's third-quarter sales, but Gilead's new drug may diminish J&J's potential.
Sanofi and partner Regeneron attached a $67.5-million priority review voucher to their experimental cholesterol drug alirocumab, making for a tighter race with Amgen.
The majority of the layoffs will be in the US.
Patent losses and lost co-promotion agreements put a dent in sales.
The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.
Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.
Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.
Executives urge analysts to focus on the company's long-term potential.
Hepatitis C medication Olysio was a star, but the company cautions competition is coming.
Analyst reaction to this week's quarterly news reflected a need to woo investors, adding to some negative carryover from the previous year.
CEO Ian Read told investors Monday that an AZ merger would benefit Astra shareholders and add oomph to its marketing potential. Another exec said he could "envision" filing palbociclib this year, but made no promises.
US sales fell 10%, and corruption allegations in China ate into emerging-market sales.
Sales of its big diabetes franchise rose 3% vs. the same period last year, while drops in Singulair and Nasonex revenue marked the quarter. The company is slated to reveal pipeline progress next week.
US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.
Sales rose 5% compared to the same period last year.
Roche also announced first-quarter sales shrank 1%.
The drugmaker expects to return emerge from 2016 with over 5,000 fewer employees and return to growth mode in 2017.
Constant exchange rates provide a positive framework for quarterly and year-end totals, whereas straight percentages indicate lower sales.
The company expects to return to growth in 2015 as it focuses on immunotherapy collaborations.
Higher prices helped insulate Q4 and annual sales, which fell and rose 2%, respectively. Lilly said its insulin glargine biosimilar will go nowhere if it is not substantially different from the competition.
Taken to new heights on the launch of MS blockbuster Tecfidera, the drug maker has raised its 2014 forecast.
Generics took a $2.2-billion bite out of sales, but growth products like Gilenya helped to minimize the impact.
The company said it may use Phase II data of a breast cancer drug for FDA review, part of an earnings presentation that also included its perspective on what a pre-2017 breakup would take.
Friday's no-nivolumab news event disappointed some, but analysts generally rooted for BMS, which saw year-end sales fall 7%, because of anticipated immuno-oncology success.
The drugmaker says 20 jobs, or 17% of its workforce, will be gone by the end of the year.
The drug maker's vision for 2014: fighting to keep Victoza top-of-mind with a US field force of around 3,000.
The company's latest numbers show generics continue to pummel sales. Former GSK-er Marc Dunoyer replaces departing CFO Simon Lowth.
Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.